Share this article Share Vaccine trials in New Zealand, Australia, Canada and the United Kingdom are set to begin next year, with a focus on isolating new infections, the first in a wave of clinical trials in developed countries, the WHO said on Wednesday.
“There are two ways that this can occur.
One, we could see a rapid increase in cases,” WHO Director-General Dr. Margaret Chan said at a briefing on vaccine trials in a major international health body.
The United States, where the first trial is under way, will follow suit in 2019, with Canada and Australia planning to launch their own trials in 2018, Chan said. “
I think that we have a great chance of seeing the emergence of some new strains and it is a great moment for the field.”
The United States, where the first trial is under way, will follow suit in 2019, with Canada and Australia planning to launch their own trials in 2018, Chan said.
Chan added that the World Health Organization has asked pharmaceutical companies to cooperate with trials in the developed world.
New Zealand has reported more than 6,000 cases of pneumococcal disease since April, with the majority of infections occurring among children.
Chan said the country had seen a sharp rise in cases, and would be conducting “dramatic trials” in 2018.
The country has seen an increase of about 300 cases a day, she said.
The WHO said the number of pneumonic cases reported from New Zealand this year is expected to reach about 100,000.
“We are not expecting an increase this year,” Chan said, adding that the WHO is “very concerned about the situation in New York, and we are working very hard to make sure that we continue to take steps to protect our populations.”
The WHO has already announced it is considering the use of an experimental vaccine for pneumonic disease, the most serious form of pneumoconiosis.
The new vaccine, known as SIVP, is being developed by a team of researchers in Japan and will be licensed for use in the United States by 2019.
The team has also proposed a pneumococcus-resistant vaccine called SRCX.
Chan warned against using the vaccine to fight the pandemic.
“If we use the vaccine, we are not going to be able to control the pandemics,” Chan told reporters in New Jersey.
Chan also said the world is in a “critical” stage of pneumonitis, the disease that has infected over 5 million people in the world, but was largely curbed by a global effort to vaccinate people.
“It’s not a good time for us to be talking about vaccines,” she said, noting that the virus had already killed more than 2 million people worldwide and that the vaccine was “the only way to fight it.”
Chan also warned that the use a vaccine against the pandemia is a risky move, as it could lead to more infections in the future.
“Let me be very clear, we should not do that,” Chan added.
“That is not the way to stop the pandics.”
The World Health Assembly will convene in September to discuss strategies to fight pneumonics, which have claimed more than 5 million lives in the past two decades.
The first phase of the trials in Australia and New Zealand has seen more than 600,000 people vaccinated, and the second phase will see trials in Japan, Canada, South Africa, Australia and China.
The vaccine trials are expected to last up to three years, Chan noted, noting there are plans to begin testing in the U.S. and the U,K.
in 2018 and 2019.
Chan praised the efforts of the WHO, and said that it is “absolutely essential” that vaccines are tested in countries where there is no vaccine available.
“This is something that we need to take very seriously,” she added.
Chan’s comments come after the WHO warned that a global pandemic is imminent, with more than half of the world’s population facing a high risk of infection, and about 15 percent of those cases being pneumonic pneumonias.
“With every passing day, more and more people around the world are becoming infected,” Chan noted.
“Every day, the number is increasing and we have to get our heads around this.” Reuters